Jones Day advises Catalent's Board of Directors in merger with Novo Holdings

Client(s) Board of Directors of Catalent Inc.

Jones Day is advising the Board of Directors of Catalent, Inc. in the $16.5 billion merger of Catalent with Novo Holdings.

Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash.

The transaction is expected to close towards the end of calendar year 2024, subject to customary closing conditions, including Catalent stockholder approval and receipt of required regulatory approvals. Following the closing of the transaction, Catalent will no longer be publicly traded on the New York Stock Exchange.

In connection with the transaction, Novo Holdings intends to sell three Catalent fill-finish sites and related assets acquired in the merger to Novo Nordisk (CPH: NOVO), in which Novo Holdings has a controlling interest. These three sites are located in Anagni, Italy; Bloomington, Indiana; and Brussels, Belgium.